Andrew Felts, Ph.D.

Drug Discovery Scientist II

     

      B.S. Psychology, University of Tennessee, Knoxville, 2000

      B.S. Chemistry, Florida State University, 2002

      Ph.D. Chemistry, Vanderbilt University, 2007
     

Phone: (615) 322-7324
Fax: (615) 322-8577
Email: a.felts@vanderbilt.edu
Location: 12410 MRB IV (Langford)

 

Biosketch and Research Interests


Andrew Felts, Ph.D., is a Research Specialist in the Lindsley Lab. Andrew obtained his doctoral and post-doctoral training at Vanderbilt University in the laboratory of Larry Marnett where his work focused on the design and synthesis of novel NSAIDs as anti-tumor agents. Using well established anti-inflammatory drugs as scaffolds he developed a novel class of compounds that were devoid of cyclooxygenase inhibitory activity but were potent inducers of apoptosis in a variety of cancer cell lines as well as activators of the nuclear transcription factor PPAR γ. These compounds represented useful probes for cyclooxygenase independent biology as well as potential leads for the development of agents for the treatment of cancer and diabetes.

 

Andrew joined Craig Lindsley’s lab in 2008 and his current research focuses on the development of allosteric modulators of mGluR5 for the treatment of schizophrenia as well as other disease states associated with mGluR5 dysfunction. It is believed that allosteric modulation of GPCRs, such as the metabotrobic glutamate receptors, will provide a much safer and therapeutically precise approach to the treatment of a variety of physiological disorders.

 

Selected Publications

Felts, A. S.; Saleh, S. A.; Le, U.; Rodriguez, A. L.; Weaver C. D.; Conn, P. J.; Lindsley, C. W.; Emmitte, K. A. Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonist of mGlu5. Bioorganic and Medicinal Chemistry Letters. 2009, 19(23), 6623-6.

Felts, A. S.; Siegel, B. S.; Young, S. M.; Moth, C. W.; Lybrand, T. P. Dannenberg, A. J.; Marnett, L. J.; Subbaramaiah, K. Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition. J. Med. Chem. 2008, 51(16), 4911-9. 

 

Felts, A. S.; Ji, C.; Stafford, S. B.; Crews, B. C.; Kingsley, P. J.; Subbaramaiah, K.; Siegel, B. S.; Young, S. M.; Dannenberg, A. J.; Marnett, L. J. Design of Indomethacin and Sulindac Derivatives that Activate PPARg and Induce Apoptosis but Lack Cyclooxygenase Inhibition. ACS Chemical Biology. 2007, 2(7), 479-83.

 

Marnett, L. J.; Prusakiewicz, J. J.; Felts, A. S.; Ji, C.; Indoleacetic Acid and Indenacetic acid Derivatives As Therapeutic Agents With Reduced Gastrointestinal Toxicity. U.S. Pat. Appl. 0250839, 2005.

 

 

 

 

Curriculum Vita

Mailing Address:

Vanderbilt University Medical Center

Department of Pharmacology

1205 Light Hall
Nashville, TN 37232-0697